I. Complete Hemp Full Spectrum

Cannacea’s phytocannabinoid-rich hemp formulations are lab-verified to provide all three major cannabis phytonutrient classes biosynthesized within the hemp inflorescence, for maximum therapeutic efficacy.

  1. Poly-Cannabinoid Synergies – Genuinely complete phytocannabinoid full spectrum.
Formulation:Tagrid’s 100Activated 40
CBD (Cannabidiol)100 mg/mL
(High strength)
~2.5 mg/drop
40 mg/mL
(Medium strength)
~1 mg/drop
Other Phytocannabinoids> 10 mg/mL> 4 mg/mL
CBC (Cannabichromene)4 mg/mL2 mg/mL
CBG (Cannabigerol)2 mg/mL1 mg/mL
CBT (Cannabicitran)1 mg/mL0.5 mg/mL
CBDV (Cannabidivarin)0.75 mg/mL0.35 mg/mL
Total THC < 1.8 mg/mL (< 0.2%)
[70:1 CBD:THC minimum]
< 1.8 mg/mL (< 0.2%)
[25:1 CBD:THC minimum]
Also quantified:CBE, CBN, CBLCBE, CBN, CBL
(for exact potencies see batch CoAs)
  1. Complete Hemp Terpene Profile – Rarely-restored natural hemp profile of volatile monoterpenes – highly therapeutic yet normally lost during hemp oil processing – alongside the less volatile sesquiterpenes.
Formulation:Tagrid’s 100Activated 40
Total Terpenes> 3 mg/mL> 2 mg/mL
Monoterpene fraction> 20%> 30%
(for exact potencies see batch CoAs)

Our clinical formulations provide key hemp terpenes, including all 8 “Terpene Super Classes” most prevalent in Cannabis sativa (marked*) [9]:



  • beta-Myrcene*
  • alpha- & beta-Pinenes*
  • Ocimene*
  • Limonene*
  • Terpinolene*
  • Linalool*
  • and many others.
  • beta-Caryophyllene*
  • Humulene*
  • Selinadiene
  • Maaliene
  • Farnesene
  • Nerolidol
  • and many others.
  1. Cannflavin A / B / C Flavonoids – exclusively biosynthesized by Cannabis sativa, comprising the largest phytochemical fraction of the plant’s formidable polyphenol content [28].
    (for exact potencies see batch CoAs)
(logarithmic % scaling)

II. Holistic Endocannabinoid Support

Cannacea provides rich phytochemical spectra from organic extractions, harnessed through targeted therapeutic ratios. Formulated through extensive research and clinical development, Cannacea respects Patient Individuality and the natural phytonutrient ratios in hemp:

  • CBD:THC ratios (minima) for varying relative THC levels and sensitivities.

  • Phytocannabinoid:Phytoterpene ratio ranges (PC:PT) for varying intakes, guided by the natural ratios in phytocannabinoid-rich hemp flower.

  • Health-conscious excipient fatty acids.

  • Graduated dropper delivery for fine-tuned intakes (+ per-drop precision).
Formulation:Tagrid’s 100Activated 40
CBD:THC > 70:1
For THC-sensitive persons requiring high CBD intakes
> 25:1
For regular adult use
PC:PTa25:1 – 35:1
Balanced toward PC effects for high intakes
15:1 – 25:1
Balanced toward natural ratio in cured hemp flower
MUFA:PUFAb> 20:1> 20:1
MUFA:SFAb> 4:1> 4:1
a PC:PT = Phytocannabinoid-to-Phytoterpene ratio.
b Fatty acid types: MUFA = Monounsaturated, PUFA = Polyunsaturated, SFA = Saturated.
(for exact potencies & ratios see batch CoAs)

III. Clinical Accuracy of Potency

Primary phytocannabinoid potency (CBD) within ± 2.5% of formulation target.
(for exact potencies & formulation accuracies see batch CoAs)

Cannacea revolutionizes the breadth of supplement constituency data available to practitioners, lab-certifying over 90% of the compounds in every batch (w/w):

  • Phytocannabinoids
  • Phytoterpenes
  • Flavonoids
  • Fatty Acids
  • Nutritional Minerals

IV. Extended Shelf Stability

Cannacea hemp oils are carefully manufactured and regularly tested for maximum shelf stability:

  • Nitrogen atmosphere bottling and headspace (minimizes oxidation).

  • Excipient fatty acid profile with reduced oxidation potential and longer life (< 5% polyunsaturates).

  • Ongoing long-range Stability Data shared with our Practitioner Partners at your request.

Science honoring Nature and her Children.







  1. Aizpurua-Olaizola, O et al. (2017). Targeting the endocannabinoid system: future therapeutic strategies. Drug Discovery Today 22(1): 105-110.
  2. Morales, P, Reggio, PH (2017). An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors. Cannabis and Cannabinoid Research 2(1): 265-273.
  3. Stasiulewicz, A et al. (2020). A Guide to Targeting the Endocannabinoid System in Drug Design. International Journal of Molecular Sciences 21(8): 2778.
  4. VanDolah, HJ et al. (2019). Clinician’s Guide to Cannabidiol and Hemp Oils. Mayo Clinic Proceedings 94(9): 1840-1851.
  5. Sholler, DJ et al. (2020). Therapeutic Efficacy of Cannabidiol (CBD): A Review of the Evidence from Clinical Trials and Human Laboratory Studies. Current Addiction Reports 7(3): 405-412.
  6. Khan, R et al. (2020). The therapeutic role of Cannabidiol in mental health: a systematic review. Journal of Cannabis Research 2:2.
  7. Abuhasira, R et al. (2018). Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. European Journal of Internal Medicine 49: 44-50.
  8. National Academies of Sciences, Engineering, and Medicine (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press.
  9. Russo, EB, Marcu, J (2017). Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads. Advances in Pharmacology 80: 67-134.
  10. Orsavova, J et al. (2015). Fatty Acids Composition of Vegetable Oils and Its Contribution to Dietary Energy Intake and Dependence of Cardiovascular Mortality on Dietary Intake of Fatty Acids. International Journal of Molecular Sciences 16(6): 12871-12890.
  11. Krut, LH, Bronte-Stewart, B (1964). The fatty acids of human depot fat. Journal of Lipid Research 5(3): 343-351.
  12. Turner, SE et al. (2017). Molecular Pharmacology of Phytocannabinoids. In Kinghorn, AD; Falk, H; Gibbons, S; Kobayashi, J (eds.). Phytocannabinoids: Unraveling the Complex Chemistry and Pharmacology of Cannabis sativa. Progress in the Chemistry of Organic Natural Products 103. Springer International Publishing: 61–101.
  13. De Petrocellis, L et al. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British Journal of Pharmacology 163(7): 1479-1494.
  14. Capano, A et al. (2020). Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgraduate Medicine 132(1): 56-61.
  15. Casarett, DJ et al. (2019). Benefit of Tetrahydrocannabinol versus Cannabidiol for Common Palliative Care Symptoms. Journal of Palliative Medicine 22(10): 1180-1184.
  16. Wagner, H, Ulrich-Merzenich, G (2009). Synergy research: Approaching a new generation of phytopharmaceuticals. Phytomedicine 16(2-3): 97-110.
  17. Rasoanaivo, P et al. (2011). Whole plant extracts versus single compounds for the treatment of malaria: synergy and positive interactions. Malaria Journal 10(Suppl.1): 1-12.
  18. Yuan, H et al. (2017). How Can Synergism of Traditional Medicines Benefit from Network Pharmacology? Molecules 22(7): 1135-1153.
  19. McPartland, JM, Russo, EB (2001). Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts? Journal of Cannabis Therapeutics 1(3-4): 103-132.
  20. Russo, E (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology 163(7): 1344-1364.
  21. Pamplona, FA et al. (2018). Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. Frontiers in Neurology 9: 759.
  22. Zafar, R et al. (2021). Medical cannabis for severe treatment resistant epilepsy in children: a case-series of 10 patients. BMJ Paediatrics Open 5: e001234.
  23. Gallily, R et al. (2015). Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol. Pharmacology and Pharmacy 6: 75-78.
  24. Lewis, MA et al. (2018). Pharmacological Foundations of Cannabis Chemovars. Planta Medica 84(04): 225-233.
  25. Karniol, IG et al. (1974). Cannabidiol interferes with the effects of delta 9- tetrahydrocannabinol in man. European Journal of Pharmacology 28(1): 172– 177.
  26. Zuardi, AW et al. (1982). Action of cannabidiol on the anxiety and other effects produced by δ9-THC in normal subjects. Psychopharmacology (Berl) 76(3): 245–250.
  27. Bhattacharyya, S et al. (2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35(3): 764-774.
  28. Izzo, L et al. (2020). Analysis of Phenolic Compounds in Commercial Cannabis sativa L. Inflorescences Using UHPLC-Q-Orbitrap HRMS. Molecules 25(3): 631.

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.